faculty

Publications

Home / Publications / A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

Groups and Associations G R Blumenschein Jr  1 , F Kabbinavar  2 , H Menon  3 , T S K Mok  4 , J Stephenson  5 , J T Beck  6 , K Lakshmaiah  7 , K Reckamp  8 , Y-J Hei  9 , K Kracht  10 , Y-N Sun  11 , R Sikorski  9 , L Schwartzberg  12 ; Motesanib NSCLC Phase II Study Investigators
Ann Oncol 2011

Abstract

Background: This phase II study estimated the difference in objective response rate (ORR) among patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) receiving paclitaxel-carboplatin (CP) plus motesanib or bevacizumab.

View Source